Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585–98.Google Scholar
Unno K, Zhou Y, Zimmerman T, Platanias LC, Wickrema A. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 2009;50:1865–71.Google Scholar
Dalmay T. MicroRNAs and cancer. J Intern Med 2008;263:366–75.Google Scholar
Lee YS, Dutta A. MicroRNAs in Cancer. Annu Rev Pathol 2009;4:199–227.Google Scholar
Bi C, Chng WJ. MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int 2014;2014:521586.Google Scholar
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828–33.Google Scholar
Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330–3.Google Scholar
Peng J, Thakur A, Zhang S, Dong Y, Wang X, Yuan R, et al. Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. Tumour Biol 2015;36: 8545–52.Google Scholar
Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 2011;309:62–70.Google Scholar
Rio-Machin A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvarez S, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype leukemia 2013;27:925–31.Google Scholar
Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol 2013;162:348–59.Google Scholar
Seckinger A, Meißner T, Moreaux J, Benes V, Hillengass J, Castoldi M, et al. miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression. Oncotarget 2015;6:39165–83.Google Scholar
Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 2011;6:23.Google Scholar
Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol 2012;29:2402–8.Google Scholar
Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78–88.Google Scholar
Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007;136:565–73.Google Scholar
Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol 2014;7:21–31.Google Scholar
Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260–70.Google Scholar
Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885–90.Google Scholar
Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. M icroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669–80.Google Scholar
Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 2010;107:7904–9.Google Scholar
Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:838–46.Google Scholar
Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 2013;54:189–91.Google Scholar
Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014;99:511–8.Google Scholar
Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012;7:e29770.Google Scholar
Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, et al. miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem 2014;51(Pt 5):543–9.Google Scholar
About the article
Published Online: 2016-05-06
Published in Print: 2017-05-01
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Grand support: the National Nature Science Foundation of China (81301498; 81271920; 81201351); Jiangsu Provincial Medical Innovation Team and Leading Talents (LJ201133); the Scientific Research Subject of Jiangsu Provincial Health Department (H201422; H201526); and translational medicine project of Affiliated Hospital of Nantong University (TDF-zh201407, TDF-zh201406).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.